I'm not chasing hype—I'm after real value. HIMS & HERS Health has skyrocketed 155% this year, but what matters to me is whether it's trading below its intrinsic value. With sticky subscriptions, strong gross margins, and zero debt, it's a legit disruptor in the health tech space, even if shareholder
1 extracted signal · 1 resolved · 0 still active
Everything MoneyIndependent analyst profile- Source published
- 05 Aug 2025, 09:54 UTC
- Recorded by Tahlil Plus
- 18 May 2026, 20:23 UTC

AI-generated source summary
The analysis covers Hims & Hers Health (HIMS), a health tech disruptor up 155% YTD. It focuses on real companies, cash flow, and opportunities, not hype. The stock chart is volatile, with significant ups and downs. The market reacts to every new story, but the analysis asks if it's selling at a fair price. The company has strong revenue with an 85% two-year retention rate on their subscription model. The ticker symbol is HIMS, and they are in telehealth, mental health, dermatology, and GLP-1 weight loss. They disrupt healthcare by reimagining the patient experience and have an economic moat factor (narrow). There are about 222 million shares outstanding (diluting shareholders), but there is zero debt. The main metric is the enterprise value. With the return on capital now positive this is a buying opportunity. Key metrics reviewed include market cap, revenue, net income, free cash flow, price to free cash flow, gross profit margin, 3Y compound revenue growth, 5-year revenue, and return on invested capital, the average investor has a hold recommendation. 10, 20, and 30 percent revenue growth for the next 10 years were assumed in the Everything Money Stock Analyzer, resulting in an intrinsic value that is 16.59% above the current stock price. There is potential to make more money using technical strategies and the smaller chart timeframes.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
Everything Money
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.
